Actively Recruiting
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Led by University Medical Centre Ljubljana · Updated on 2024-08-07
10
Participants Needed
3
Research Sites
59 weeks
Total Duration
On this page
Sponsors
U
University Medical Centre Ljubljana
Lead Sponsor
S
Stanford University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patients with heart failure with preserved ejection fraction, and decreased the heart failure hospitalizations in patients with type 2 diabetes. The aim of the present study is to investigate the underlying mechanisms of the beneficial clinical effects of semaglutide in the setting of chronic heart failure.
CONDITIONS
Official Title
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 20 and 80 years
- Diagnosis of heart failure
- Body mass index of 27 kg/m2 or greater
- Stable and optimal heart failure therapy doses for at least 3 months
- N-terminal pro B-type natriuretic peptide levels greater than 350 pg/mL
You will not qualify if you...
- Diagnosis of type 1 or type 2 diabetes or Hemoglobin A1c higher than 6.5%
- Pregnancy or potential to become pregnant
- Cancer
- Liver dysfunction with enzyme levels more than 3 times the normal upper limit or high bilirubin
- Kidney dysfunction with estimated glomerular filtration rate below 25 mL/min/1.73 m2
- Hospitalization within the last 3 months for reasons other than heart failure
- New York Heart Association functional class I or IV symptoms
- Previous or planned bariatric surgery
- Weight change greater than 11 lbs (5 kg) in the 3 months before enrollment
- Acute or chronic infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Greenstone Biosciences
Palo Alto, California, United States, 94304
Actively Recruiting
2
Stanford Cardiovascular Institute
Stanford, California, United States, 94305
Actively Recruiting
3
University Medical Center Ljubljana
Ljubljana, Slovenia, 1000
Actively Recruiting
Research Team
B
Bojan Vrtovec, MD, PhD
CONTACT
S
Sabina Frljak, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here